RiverVest Venture Partners — 2016 Investments
3 investments dated 2016 · listed companies and verified rows first · show all
AnTolRx develops immunotherapy therapeutics based on research in immune tolerance, targeting immune-mediated disorders.
BiotechHealthtechBoston, US
Francisco J. Quintana(Scientific Founder, Member of Board of Directors)Mark Carthy(Founder and CEO, Member of Board of Directors)
BoardSatish Jindal(Director)
Co-investorsAvego BioScience CapitalBioGenerator VenturesPerot JainRoche Venture FundSR One Capital Management
Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options.
BiotechSan Francisco, US
Agnes Rafalko(Executive Officer, Director)inSteven Axon(Chief Executive Officer)inHicham Alaoui(Chief Scientific Officer)inRose Marino(Chief Medical Officer)inPeter McWilliams(Chief Business Officer)Geoffrey Hird(Chief Technology Officer)in
Co-investorsAdvent Life SciencesAsahi Kasei Corporate Venture CapitalChiesi VenturesCTI Life Sciences Fund L.P.Mission Bay CapitalMission Biocapital+6 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.











